Regular paperAnalysis of the vasodilator action of Alprenolol (cas 13655-52-2)
-
Add time:09/24/2019 Source:sciencedirect.com
The effect of alprenolol and other β-adrenoceptor antagonists, including d-isomers, on blood flow in femoral, coronary and mesenteric vascular beds was measured in anesthetized dogs. Under conditions of constant perfusion pressure, intra-arterial injection of β-adrenoceptor antagonists produced vasodilation. Propranolol and alprenolol were approximately equipotent in coronary and mesenteric beds but alprenolol was significantly more potent in the femoral bed. Practolol was virtually inactive in all beds. The vasodilating potency of d-alprenolol and d-propranolol was not significantly different from that of the respective racemic mixtures. The vasodilator response to alprenolol was not affected by pretreatment with atropine, diphenhydramine or propranolol. In conscious normotensive dogs i.v. injections of d,1- and d-alprenolol produced dose-dependent decreases in blood presscious normotensive dogs i.v. injections of d,1- and d-alprenolol produced dose-dependent decreases in blood pressure and increases in heart rate. Under similar conditions, i.v. d,1-propranolol was without effect on either measurement. The results suggest that the hypotensive action of alprenolol in dogs may derive from its vasodilator activity.
We also recommend Trading Suppliers and Manufacturers of Alprenolol (cas 13655-52-2). Pls Click Website Link as below: cas 13655-52-2 suppliers
Prev:Nasal absorption of Alprenolol (cas 13655-52-2) and metoprolol
Next:Gel formulations containing catanionic vesicles composed of Alprenolol (cas 13655-52-2) and SDS: Effects of drug release and skin penetration on aggregate structure) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Combined pharmacokinetic and pharmacodynamic studies on Alprenolol (cas 13655-52-2) and 4-hydroxy-Alprenolol (cas 13655-52-2) in man09/27/2019
- Microcalorimetric studies on the complex formation between cellobiohydrolase I (CBH I) from Trichoderma reesei and the (R)- and (S)-enantiomers of the β-receptor blocking agent Alprenolol (cas 13655-52-2)09/26/2019
- Gel formulations containing catanionic vesicles composed of Alprenolol (cas 13655-52-2) and SDS: Effects of drug release and skin penetration on aggregate structure09/25/2019
- Nasal absorption of Alprenolol (cas 13655-52-2) and metoprolol09/10/2019
- Enantioselective determination of Alprenolol (cas 13655-52-2) in human plasma by liquid chromatography with tandem mass spectrometry using cellobiohydrolase chiral stationary phases09/09/2019
- Electrophoretic behavior of Alprenolol (cas 13655-52-2) in mixed solvent electrolyte systems09/08/2019
- Enantioselective biodegradation of pharmaceuticals, Alprenolol (cas 13655-52-2) and propranolol, by an activated sludge inoculum09/07/2019
- Labeling of Alprenolol (cas 13655-52-2) with fluorescent aryl iodide as a reagent based on Mizoroki–Heck coupling reaction09/06/2019
- Quantification of Alprenolol (cas 13655-52-2) and propranolol in human plasma using a two-dimensional liquid chromatography (2D-LC)09/05/2019


